We are excited to share that EDDC is the co-organizer of a session showcasing Singapore’s biotech ecosystem at BIO Asia–Taiwan 2022!This virtual session is on-demand and will feature the Consortium for Clinical Research and Innovation, Singapore (CRIS), Hummingbird Bioscience, Engine Biosciences, DotBio and MediSix Therapeutics. BIO Asia-Taiwan 2022 is a hybrid event this year, running […]
BIO Asia-Taiwan 2022 Read More »
Enabling Your Research with Tech Access Webinar SeriesEDDC’s fee-for-service arm, EARO, leverages on our expert know-how and technologies to offer ISO-certified technical support and consultation to early-stage drug discovery researchers. To date, EARO has successfully supported 161 projects from academia, local biotech and MNCs.To find out more about how EARO can help fast track your
Enabling your research with tech access webinar series Read More »
EDDC is attending BIO 2022 this year!Our CEO, Damian O’Connell and BD representative Jingli Zhuo will be attending this event.If you are attending BIO 2022, log on to the BIO partnering system and request a meeting with us! We are excited to meet with potential corporate partners and collaborators. See you there!
EDDC’s EARO announces successful ISO-9001:2015 certificationEDDC’s Academic Research Organization (EARO) is the fee-for-service arm of EDDC.We are proud to announce EARO (EDDC Academic Research Organization)’s successful ISO-9001:2015 certification! This is an official recognition of EARO’s ability to consistently provide services at a high quality standard. EARO is a fee-for-service initiative by EDDC that offers services
EDDC’s EARO announces successful ISO-9001:2015 certification Read More »
EDDC is attending ASCO 2022 this year!Our CEO, Damian O’Connell, will be attending this event in-person. He will be accompanied by our Medical Director, Venkateshan SP, and Asset Development Leader, Veronica Diermayr PhD, as well. We are excited to share that EDDC will be attending this year’s ASCO conference! After being away for the last
EDDC’s Biomarker team analysing samples from ETC-159 trialA made-in-Singapore cancer drug, ETC-159, has advanced into the dose expansion portion of its Phase 1B clinical trial. The Phase 1B dose expansion study tests the preliminary efficacy and safety of ETC-159 in a subset of genetically defined patients with microsatellite stable (MSS)1 cancers. MSS tumours have few
Made-In-Singapore Cancer Drug ETC-159 Advances In Clinical Trials Read More »
The following text is adapted from this press release. EDDC staff planning the automation of an antibody engineering process. Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies These engineered antibodies may allow for specific targeting of tumor cells without binding to healthy cells
In 2018, local biotech start-up AUM Biosciences (AUM) was looking to kick-off an “Asia to Global” vision through a focus on developing therapeutics for Asia-Pacific cancers, which could also be delivered to Western markets. That year, the oncology research company licensed ETC-206, now known as AUM001, a MNK inhibitor that was developed by a legacy
EDDC interviews AUM Biosciences CEO, Mr. Vishal Doshi Read More »
Everest gains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19 Everest will have sub-licensing rights and full technology transfer Licensing of 3CL protease inhibitor oral treatment is expected to complement Everest’s COVID-19 vaccine program Clinical trials evaluating lead asset EDDC-2214 expected to start later this year Shanghai, China — January
TTC Video Series – Considerations in Drug DiscoveryA series of 9 videos to inform and educate scientists on the potential pitfalls in their drug discovery journey and advice how to overcome them.Behind the scenes of one of the recording sessions with in-house experts. Our Quality Assurance colleague, Yu Lan, hosts this session with Christophe Bodenreider,
